Open AccessLong-term Results of the PRESERFLO MicroShunt in Patients With Primary Open-angle Glaucoma From a Single-center Nonrandomized Study
Author(s) -
Juan F. Batlle,
Adalgisa Corona,
Rachel Gimenes Albuquerque
Publication year - 2020
Publication title -
journal of glaucoma
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.11
H-Index - 88
eISSN - 1536-481X
pISSN - 1057-0829
DOI - 10.1097/ijg.0000000000001734
Subject(s) - medicine , glaucoma , intraocular pressure , adverse effect , ophthalmology , glaucoma medication , open angle glaucoma , single center , trabeculectomy , incidence (geometry) , cataract surgery , surgery , physics , optics
The MicroShunt was implanted in 23 patients with primary open-angle glaucoma (POAG) in a feasibility study. Reductions in intraocular pressure (IOP) and medications were sustained for up to 5 years with no long-term sight-threatening adverse events (AEs).